Actavis Claims Cancer Drug Patents Are Invalid

By Ron Zapata

Law360, New York (September 20, 2007, 12:00 AM ET) -- Actavis Group hf has struck back against a lawsuit filed by Sanofi-Aventis U.S. LLC alleging infringement of a patent for Eloxatin, saying it is not violating patents for the colon cancer drug.

Actavis and its subsidiaries filed an answer and counterclaims on Wednesday to Sanofi-Aventis’ lawsuit in the U.S. District Court for the District of New Jersey, denying charges that the Iceland-based generic drug maker has infringed on an Eloxatin patent through its abbreviated new drug application filed with the U.S. Food and Drug Administration....
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles